Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2022-04-27 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2021 年年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, important matters, shareholder information, and financial statements. The document includes audited financial data, signatures from company officers and auditors, and comprehensive financial and operational information for the fiscal year 2021. The length is substantial (15,000 characters), and it is the full report, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-27 Chinese
独立董事关于2021年度报告有关事项的事前认可
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval on matters related to the 2021 annual report, specifically regarding anticipated related party transactions and the reappointment of the audit firm for 2022. It references regulatory compliance and expresses opinions on proposals to be submitted to the board and shareholders. The document is short (518 characters) and does not contain financial statements or detailed financial data. It is essentially an approval or certification related to governance and audit matters, not the full annual report or audit report itself. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement rather than a full report or audit document.
2022-04-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's ninth board meeting, detailing the approval of the 2021 annual report, board work report, financial report, profit distribution plan, remuneration, internal control evaluation, and other governance matters. It references the 2021 annual report and other reports but does not contain the full annual report itself. The document is relatively short (2292 characters) and mainly announces board decisions and approvals, with many references to full reports disclosed elsewhere. This fits the profile of a Board/Management Information filing, as it announces board resolutions and management decisions rather than providing the full annual report or financial statements. Therefore, the correct classification is MANG (Board/Management Information).
2022-04-27 Chinese
2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2021 Annual Report Summary" of 江苏四环生物股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including total assets, net profit, revenue, quarterly financial data, shareholder information, and business overview. The presence of comprehensive financial statements and business descriptions for the full fiscal year 2021 aligns with the characteristics of an Annual Report (10-K). The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or a certification. Therefore, it is classified as an Annual Report (10-K). FY 2021
2022-04-27 Chinese
江苏四环生物股份有限公司独立董事2021年度述职报告(刘卫）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 by an independent director of Jiangsu Sihuan Bio Co., Ltd. It details the director's attendance at board meetings, independent opinions on various board resolutions, supervisory activities, and efforts to protect investor rights. The content focuses on the director's duties and governance oversight rather than financial results or audit opinions. It is not a full annual report, audit report, or earnings release. It is a management/governance-related report describing board activities and director responsibilities. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2022-04-27 Chinese
江苏四环生物股份有限公司2021年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度监事会工作报告' which translates to '2021 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, and opinions on the company's operations, financial status, internal controls, and compliance with laws during the 2021 fiscal year. It includes references to the review and approval of the 2020 annual report, quarterly reports, and internal control evaluation reports. The content is a detailed report from the supervisory board on their oversight and findings for the year, which aligns with the nature of an Audit Report / Information (AR) as it focuses on audit-related supervisory activities and internal control assessments rather than the full annual report or other types of filings. The document length is 1519 characters, which is relatively short but contains substantive supervisory and audit-related content, not merely an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2021
2022-04-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.